Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results, Beats Expectations By $0.05 EPS

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.05, Zacks reports. The business had revenue of $40.78 million during the quarter, compared to analysts' expectations of $37.37 million. Heron Therapeutics updated its FY 2025 guidance to EPS.

Heron Therapeutics Trading Down 9.3 %

HRTX stock traded down $0.23 during trading on Monday, reaching $2.24. 3,230,465 shares of the stock were exchanged, compared to its average volume of 1,797,269. The firm has a market capitalization of $340.69 million, a price-to-earnings ratio of -12.44 and a beta of 1.60. The business has a 50 day moving average price of $1.69 and a 200-day moving average price of $1.71. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93.

Analysts Set New Price Targets

A number of research analysts have weighed in on HRTX shares. Needham & Company LLC reissued a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday. StockNews.com upgraded Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.